Awards Nomination 20+ Million Readerbase
PMC/PubMed Indexed Articles

Statistical considerations in biosimilar assessment using biosimilarity index

In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation

View More »

Google Scholar citation report
Citations : 4890

Journal of Bioequivalence & Bioavailability received 4890 citations as per Google Scholar report

Journal of Bioequivalence & Bioavailability
Journal of Bioequivalence & Bioavailability peer review process verified at publons
Flyer image
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
View More
Useful Links
Share This Page
Journal Flyer
Journal of Bioequivalence & Bioavailability
Open Access Journals
View More

Jeff Paul

Jeff Paul

Pfizer Inc, formerly Wyeth Research, Collegeville, Pennsylvania, USA

Biography
Dr. Paul is a clinical pharmacology consultant to the pharmaceutical industry, focusing his practice on early clinical development of drugs for CNS and pain. Dr. Paul has spent nearly 30 years in pharmaceutical R&D, including Discovery, and Phase 1 through 4 clinical development phases. He has global clinical and regulatory experience, especially in Europe and Japan. He has worked at Berlex, Pfizer (formally Wyeth), and Astellas at the Executive Director/Assistant VP level.